For an enterprise, what is important is to have the self-dependent innovation ability so that it can en- hance the core competence unceasingly and acquire sustainable competitive advantages. In this paper, the indi- c...For an enterprise, what is important is to have the self-dependent innovation ability so that it can en- hance the core competence unceasingly and acquire sustainable competitive advantages. In this paper, the indi- cator system of the self-dependent innovation ability of equipment manufacturing enterprises in Shaanxi province is constructed, in which includes 4 one-level indicators and 13 two-level indicators; and conducts empirical re- search by applying the multi-level fuzzy comprehensive evaluation method.展开更多
Objective:To determine the impact of major disease epidemics on pharmaceutical manufacturing firms'Research&Development(R&D)investments and economic consequences.Methods:The sample consists of 1582 firm-ye...Objective:To determine the impact of major disease epidemics on pharmaceutical manufacturing firms'Research&Development(R&D)investments and economic consequences.Methods:The sample consists of 1582 firm-year observations from 2009 to 2022 in China,of which,26.6%of pharmaceutical companies are involved in the diagnosis and treatment of prevalent diseases.Linear models using R&D investments,patent applications,operating performances and stock returns as dependent variables are constructed separately to examine the response of pharmaceutical companies to disease epidemics and the resulting economic consequences.Results:The prevalence of five major diseases led to a 17.5%increase in the amount of R&D investment and an 87.8%rise in the ratio of R&D investment to total assets by disease-related pharmaceutical companies,compared to unrelated pharmaceutical companies.Further evidence indicated that the patent applications for disease-related firms increased by 44.3%relative to unrelated firms after the epidemics.Though the impacts of the epidemics on firms’operating performances were insignificant in the short term,a major disease epidemic was associated with an increase in stock returns of 67.4%and 44.6%,respectively,as measured by the capital asset pricing model and Fama-French five-factor model.Additional analysis revealed that the impacts of the epidemics on R&D investments and patent applications were more pronounced for non-state-owned enterprises than state-owned enterprises.Conclusions:This study demonstrates that disease-related pharmaceutical firms respond to the disease epidemics through increasing R&D investment.More patent applications and higher market value are the main gains from the firms’increased investments in R&D following the epidemic,rather than the improvements of short-term operating performances.展开更多
基金supported by Fund for Higher Education Research of Northwestern Polytechnical University under Grant No.2012GJY19
文摘For an enterprise, what is important is to have the self-dependent innovation ability so that it can en- hance the core competence unceasingly and acquire sustainable competitive advantages. In this paper, the indi- cator system of the self-dependent innovation ability of equipment manufacturing enterprises in Shaanxi province is constructed, in which includes 4 one-level indicators and 13 two-level indicators; and conducts empirical re- search by applying the multi-level fuzzy comprehensive evaluation method.
基金supported by the National Natural Science Foundation of China (No.71903030)the Natural Science Foundation of Fujian Province (No.2020J01562)the Funds for Distinguished Young Scientists of Fujian Agriculture and Forestry University (No.XJQ2020S3).
文摘Objective:To determine the impact of major disease epidemics on pharmaceutical manufacturing firms'Research&Development(R&D)investments and economic consequences.Methods:The sample consists of 1582 firm-year observations from 2009 to 2022 in China,of which,26.6%of pharmaceutical companies are involved in the diagnosis and treatment of prevalent diseases.Linear models using R&D investments,patent applications,operating performances and stock returns as dependent variables are constructed separately to examine the response of pharmaceutical companies to disease epidemics and the resulting economic consequences.Results:The prevalence of five major diseases led to a 17.5%increase in the amount of R&D investment and an 87.8%rise in the ratio of R&D investment to total assets by disease-related pharmaceutical companies,compared to unrelated pharmaceutical companies.Further evidence indicated that the patent applications for disease-related firms increased by 44.3%relative to unrelated firms after the epidemics.Though the impacts of the epidemics on firms’operating performances were insignificant in the short term,a major disease epidemic was associated with an increase in stock returns of 67.4%and 44.6%,respectively,as measured by the capital asset pricing model and Fama-French five-factor model.Additional analysis revealed that the impacts of the epidemics on R&D investments and patent applications were more pronounced for non-state-owned enterprises than state-owned enterprises.Conclusions:This study demonstrates that disease-related pharmaceutical firms respond to the disease epidemics through increasing R&D investment.More patent applications and higher market value are the main gains from the firms’increased investments in R&D following the epidemic,rather than the improvements of short-term operating performances.
